DE69729391T2 - Hochdosierte liposomale aerosolformulierung - Google Patents
Hochdosierte liposomale aerosolformulierung Download PDFInfo
- Publication number
- DE69729391T2 DE69729391T2 DE69729391T DE69729391T DE69729391T2 DE 69729391 T2 DE69729391 T2 DE 69729391T2 DE 69729391 T DE69729391 T DE 69729391T DE 69729391 T DE69729391 T DE 69729391T DE 69729391 T2 DE69729391 T2 DE 69729391T2
- Authority
- DE
- Germany
- Prior art keywords
- cyclosporin
- liposomes
- dlpc
- aerosol
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 123
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 238000009472 formulation Methods 0.000 title description 54
- 239000002502 liposome Substances 0.000 claims abstract description 142
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 105
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 105
- 108010036949 Cyclosporine Proteins 0.000 claims abstract description 105
- 229960001265 ciclosporin Drugs 0.000 claims abstract description 105
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 20
- 229930182912 cyclosporin Natural products 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 210000002969 egg yolk Anatomy 0.000 claims description 3
- 230000009610 hypersensitivity Effects 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 235000013345 egg yolk Nutrition 0.000 claims description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 abstract description 14
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract description 13
- 150000001875 compounds Chemical class 0.000 abstract description 8
- 239000003862 glucocorticoid Substances 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 59
- 229940079593 drug Drugs 0.000 description 57
- 210000004072 lung Anatomy 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000004128 high performance liquid chromatography Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000012071 phase Substances 0.000 description 10
- 238000004544 sputter deposition Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000006199 nebulizer Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000007306 turnover Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 238000004088 simulation Methods 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 102000003896 Myeloperoxidases Human genes 0.000 description 3
- 108090000235 Myeloperoxidases Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000000889 atomisation Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 206010029888 Obliterative bronchiolitis Diseases 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- 201000003848 bronchiolitis obliterans Diseases 0.000 description 2
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000001370 mediastinum Anatomy 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- -1 Budesonide lipid Chemical class 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229940127022 high-dose drug Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical group [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US731605 | 1976-10-12 | ||
| US675654 | 1991-03-27 | ||
| US67565496A | 1996-07-03 | 1996-07-03 | |
| US08/731,605 US5958378A (en) | 1996-07-03 | 1996-10-16 | High dose liposomal aerosol formulations containing cyclosporin A or budesonide |
| PCT/US1997/011696 WO1998000111A1 (en) | 1996-07-03 | 1997-07-02 | High dose liposomal aerosol formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69729391D1 DE69729391D1 (de) | 2004-07-08 |
| DE69729391T2 true DE69729391T2 (de) | 2005-06-02 |
Family
ID=27101390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69736083T Expired - Lifetime DE69736083T2 (de) | 1996-07-03 | 1997-07-02 | Hochdosierte liposomale Aerosolformulierung |
| DE69729391T Expired - Lifetime DE69729391T2 (de) | 1996-07-03 | 1997-07-02 | Hochdosierte liposomale aerosolformulierung |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69736083T Expired - Lifetime DE69736083T2 (de) | 1996-07-03 | 1997-07-02 | Hochdosierte liposomale Aerosolformulierung |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0959874B1 (enExample) |
| JP (1) | JP2001524930A (enExample) |
| CN (1) | CN1094345C (enExample) |
| AT (2) | ATE328583T1 (enExample) |
| AU (1) | AU732124B2 (enExample) |
| CA (1) | CA2259185C (enExample) |
| DE (2) | DE69736083T2 (enExample) |
| NZ (1) | NZ333497A (enExample) |
| TW (1) | TW497974B (enExample) |
| WO (1) | WO1998000111A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6417172B1 (en) * | 1995-06-05 | 2002-07-09 | Eisai Co., Ltd. | Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
| US5863910A (en) * | 1996-01-12 | 1999-01-26 | Bolonick; Joel | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
| US6090407A (en) | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
| US7348025B2 (en) | 1997-09-23 | 2008-03-25 | Research Development Foundation | Small particle liposome aerosols for delivery of anticancer drugs |
| US6946117B1 (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
| US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US20020006901A1 (en) | 1999-02-05 | 2002-01-17 | Aldo T. Iacono | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
| EP1189597A4 (en) * | 1999-06-04 | 2008-06-18 | Pacira Pharmaceuticals Inc | COMPOSITIONS USING AN OIL CORE FOR DELAYED RELEASE HYDROPHOLE MEDICAMENTS |
| AU777338B2 (en) * | 1999-12-04 | 2004-10-14 | Research Development Foundation | Carbon dioxide enhancement of inhalation therapy |
| US7442388B2 (en) | 2000-05-10 | 2008-10-28 | Weers Jeffry G | Phospholipid-based powders for drug delivery |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| WO2003053411A1 (en) | 2001-12-19 | 2003-07-03 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
| CA2486622A1 (en) * | 2002-05-20 | 2003-12-04 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
| US20050255154A1 (en) | 2004-05-11 | 2005-11-17 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
| JP5846711B2 (ja) | 2005-06-09 | 2016-01-20 | メダ アーベー | 炎症性疾患の治療のための方法及び組成物 |
| DE102006051512A1 (de) * | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
| CN101502484B (zh) * | 2006-12-26 | 2011-04-20 | 济南康泉医药科技有限公司 | 同载糖皮质激素和化疗药物的抗癌缓释剂 |
| CA2705159A1 (en) * | 2007-11-09 | 2009-05-14 | Map Pharmaceuticals, Inc. | Methods for administering corticosteroid formulations |
| BR112012022916B1 (pt) | 2010-03-12 | 2021-11-09 | Berg Llc | Formulações intravenosas de coenzima q10 (coq10), bem como método de preparação e uso da mesma |
| US20120028335A1 (en) | 2010-07-28 | 2012-02-02 | Life Technologies Corporation | Anti-viral azide-containing compounds |
| US20130209550A1 (en) | 2010-07-28 | 2013-08-15 | Life Technologies Corporation | Anti-Viral Azide Containing Compounds |
| JP2013532722A (ja) * | 2010-08-05 | 2013-08-19 | ピラマル エンタープライジーズ リミテッド | 感染症治療用抗感染性分子の経肺薬物送達用微粒子製剤 |
| CN102008713B (zh) * | 2010-12-02 | 2012-10-24 | 深圳海王药业有限公司 | 环孢素a前体脂质体、药物组合物及其制备方法 |
| CN107095863A (zh) * | 2011-06-17 | 2017-08-29 | 博格有限责任公司 | 可吸入药物组合物 |
| GB201114332D0 (en) | 2011-08-19 | 2011-10-05 | Nufarm Uk Ltd | Novel inhibitor compositions and methods of use |
| SG11201404361UA (en) | 2012-01-26 | 2014-09-26 | Life Technologies Corp | Methods for increasing the infectivity of viruses |
| AU2019294975B2 (en) * | 2018-06-27 | 2024-11-07 | Breath Therapeutics Gmbh | Inhalable compositions comprising macrocyclic immunosuppressants |
| EP3813788A1 (en) * | 2018-06-27 | 2021-05-05 | Breath Therapeutics GmbH | Pharmaceutical compositions in lyophilized form |
| EA202092892A1 (ru) | 2018-12-04 | 2021-05-27 | Брес Терапьютикс Гмбх | Ингаляционные композиции, содержащие макроциклические иммуносупрессанты |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8403905D0 (sv) * | 1984-07-30 | 1984-07-30 | Draco Ab | Liposomes and steroid esters |
| SE8603812D0 (sv) * | 1986-09-12 | 1986-09-12 | Draco Ab | Administration of liposomes to mammals |
| IE63869B1 (en) * | 1986-11-06 | 1995-06-14 | Res Dev Foundation | Aerosols containing liposomes and method for their preparation |
| US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| MX9201782A (es) * | 1991-04-19 | 1992-10-01 | Sandoz Ag | Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene. |
| DE4203306A1 (de) * | 1992-02-06 | 1993-08-12 | Ig Spruehtechnik Gmbh | Asthma oder pulmonal-aerosolzubereitungen mit lecithin |
| AR002009A1 (es) * | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
-
1997
- 1997-02-17 TW TW086101859A patent/TW497974B/zh not_active IP Right Cessation
- 1997-07-02 AU AU36508/97A patent/AU732124B2/en not_active Ceased
- 1997-07-02 CA CA002259185A patent/CA2259185C/en not_active Expired - Fee Related
- 1997-07-02 JP JP50449998A patent/JP2001524930A/ja active Pending
- 1997-07-02 EP EP97933287A patent/EP0959874B1/en not_active Expired - Lifetime
- 1997-07-02 DE DE69736083T patent/DE69736083T2/de not_active Expired - Lifetime
- 1997-07-02 CN CN97196141A patent/CN1094345C/zh not_active Expired - Fee Related
- 1997-07-02 AT AT04009645T patent/ATE328583T1/de not_active IP Right Cessation
- 1997-07-02 DE DE69729391T patent/DE69729391T2/de not_active Expired - Lifetime
- 1997-07-02 AT AT97933287T patent/ATE268163T1/de not_active IP Right Cessation
- 1997-07-02 NZ NZ333497A patent/NZ333497A/en not_active IP Right Cessation
- 1997-07-02 WO PCT/US1997/011696 patent/WO1998000111A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001524930A (ja) | 2001-12-04 |
| EP0959874B1 (en) | 2004-06-02 |
| CA2259185C (en) | 2009-12-15 |
| EP0959874A4 (enExample) | 1999-12-22 |
| CN1094345C (zh) | 2002-11-20 |
| AU3650897A (en) | 1998-01-21 |
| ATE268163T1 (de) | 2004-06-15 |
| ATE328583T1 (de) | 2006-06-15 |
| TW497974B (en) | 2002-08-11 |
| WO1998000111A1 (en) | 1998-01-08 |
| AU732124B2 (en) | 2001-04-12 |
| CN1224347A (zh) | 1999-07-28 |
| NZ333497A (en) | 2000-06-23 |
| DE69736083T2 (de) | 2006-12-28 |
| DE69736083D1 (de) | 2006-07-20 |
| CA2259185A1 (en) | 1998-01-08 |
| EP0959874A1 (en) | 1999-12-01 |
| DE69729391D1 (de) | 2004-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69729391T2 (de) | Hochdosierte liposomale aerosolformulierung | |
| US5958378A (en) | High dose liposomal aerosol formulations containing cyclosporin A or budesonide | |
| DE60107862T2 (de) | Inhalationspartikel bestehend aus mindestens zwei wirkstoffen | |
| DE3686025T2 (de) | Verfahren und system zum einatmen von liposomen. | |
| DE3750537T2 (de) | Aerosole, die Liposome beinhalten, und Verfahren zu deren Herstellung. | |
| DE69033856T2 (de) | Verabreichungssystem für phospholipide | |
| DE69928665T2 (de) | Kortikosteroide enthaltende wässrige Zusammensetzungen zum nasalen oder pulmonalen Zuführen | |
| AT389993B (de) | Herstellung von aerosolzusammensetzungen | |
| DE4208258B4 (de) | Verfahren zur Herstellung von kristallinem Ciclosporin in kugelartiger Teilchenform und seine Verwendung, insbesondere zur pulmonalen Verabreichung | |
| DE69634246T2 (de) | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit | |
| EP0760649B1 (en) | Fluticasone propionate formulations | |
| DE69636961T2 (de) | Pulver zur Verwendung in Trockenpulverinhalatoren | |
| DE69709722T2 (de) | Mikrokugeln aus polysaccharid zur pulmonaren wirkstoffabgabe | |
| DE69933472T2 (de) | Pulmonale arzneistoffverabreichung | |
| DE69909127T2 (de) | Aerosol formulierungen für buccale und pulmonale anwendung | |
| DE69925849T2 (de) | Verabreichung von einem aerosolisierten wirkstoff unter moduliertem strömungswiderstand | |
| DE3783039T2 (de) | Membran lipid zusammensetzung und verfahren zur herstellung. | |
| DE60036214T2 (de) | Verfahren und system zur herstellung von trockenem pulver mittels sprühtrocknung | |
| WO2000045878A2 (de) | Druckluftinhalator zur pulmonalen applikation liposomalen pulver-aerosols sowie dafür geeignete pulver-aerosole | |
| DE60107863T2 (de) | Kombinationspartikel für die behandlung von asthma | |
| DE4216644B4 (de) | Liposomen enthaltende Arzneimittel | |
| EP2526927A1 (de) | Biokompatible Nano- und Mikropartikel beschichtet mit Stabilisatoren für die pulmonale Applikation | |
| DE102009031274A1 (de) | Liposomen zur pulmonalen Applikation | |
| DE60023547T3 (de) | PARTIKEL ZUR INHALATION: Herstellungsmethode | |
| DE69804998T2 (de) | Mometasonfuroat-suspensionen zum zerstäuben |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |